Highnoon Laboratories Limited has placed a detailed account of its related party transactions for shareholder consideration ahead of its Annual General Meeting scheduled for April 30, 2026, highlighting extensive financial dealings with subsidiaries and associated companies during 2025. The disclosures provide transparency into the company’s integrated operational structure.
Read More: Supernet Secures Fresh 5-Year Banking Cybersecurity Contract with Major Pakistani Bank
The company’s disclosures show significant business activity with its wholly owned subsidiary Curexa Health (Private) Limited , where sales reached Rs526.6 million during 2025, alongside purchases of Rs231.7 million.
Transactions with Curexa Health (Wholly Owned Subsidiary)
| Transaction Type | Amount (Rs) |
|---|---|
| Sales | 526.6 million |
| Purchases | 231.7 million |
| Royalty Income | 4.48 million |
| Sale of Fixed Assets | 38.3 million |
| Receipts | 220.8 million |
| Loan Extended | 425.0 million |
| Equity Investment | 125.0 million |
| Interest Income on Loan | 7.59 million |
| Receivables Adjusted Against Loan | 150.7 million |
Financial Support to Subsidiary
Highnoon also extended financial support to its subsidiary through a Rs425 million loan and made an equity investment of Rs125 million , showing continued capital backing. Interest income on the loan stood at Rs7.59 million, while receivables amounting to Rs150.7 million were adjusted against outstanding loan balances.
Transactions with Route 2 Health (Associate)
Transactions with associate Route 2 Health (Private) Limited also remained notable, with net sales recorded at Rs115.3 million. The company earned royalty income of Rs6.35 million and posted receipts of Rs127 million. Dividend flows from this associate amounted to Rs9.52 million.
| Transaction Type | Amount (Rs) |
|---|---|
| Net Sales | 115.3 million |
| Royalty Income | 6.35 million |
| Receipts | 127.0 million |
| Dividend Income | 9.52 million |
Investment Returns from Pharmatec
Meanwhile, investment-linked returns from Pharmatec Investments Limited contributed significantly, with dividends declared at Rs176.6 million during 2025.
Employee Benefits
The disclosures further outline contributions to staff retirement and welfare funds exceeding Rs88 million , indicating ongoing commitments to employee benefit structures.
Governance and Compliance
All transactions were carried out in the ordinary course of business and underwent review by the board and audit committee, with shareholders set to evaluate and ratify these dealings. The move aligns with regulatory requirements, ensuring transparency in financial relationships within the group.
About Highnoon Laboratories Limited
Highnoon Laboratories Limited (PSX: HINOON) is a leading pharmaceutical company in Pakistan, engaged in the manufacturing, importing, and marketing of a wide range of therapeutic products. The company operates through various subsidiaries and associated entities, including Curexa Health (Private) Limited, Route 2 Health (Private) Limited, and Pharmatec Investments Limited.
About Curexa Health
Curexa Health (Private) Limited is a wholly owned subsidiary of Highnoon Laboratories, producing antibiotics, particularly cephalosporins, through cGMP-compliant facilities for both local and international markets.
About the Annual General Meeting
The Annual General Meeting (AGM) of Highnoon Laboratories Limited is scheduled for April 30, 2026, where shareholders will evaluate and ratify the related party transactions disclosed for the year 2025.
